ALLERGAN INC, (AGN) Stock Research Free Stock Rating

Company Profile

Allergan, Inc. engages in the development and commercialization of pharmaceutical products for the ophthalmic, neurological, dermatological, and other markets. It engages in pharmaceutical research, targeting products and technologies related to disease areas, such as glaucoma, retinal disease, dry eye, psoriasis, acne, and movement disorders. The company also offers aesthetic-related pharmaceuticals and over the counter products. Allergan offers prescription and nonprescription products to treat diseases and disorders of the eye, including glaucoma, dry eye, inflammation, infection, and allergy. Its glaucoma treatment products include Alphagan, a brimonidine tartrate ophthalmic solution; Alphagan P, a brimonidine tartrate ophthalmic solution; Lumigan, a bimatoprost ophthalmic solution; and Restasis, a cyclosporine ophthalmic emulsion. Its ophthalmic anti-inflammatory products include Acular and Acular LS, as well as Pred Forte, a topical steroid. Acular is indicated for the temporary relief of itch associated with seasonal allergic conjunctivitis, the inflammation of the mucus membrane, and for the treatment of post operative inflammation in patients who have undergone cataract extraction. Acular LS is used for the reduction of ocular pain, burning, and stinging following corneal refractive surgery. The company’s ophthalmic infection treatment products include Ocuflox, Oflox, Zymar, and Exocin ophthalmic solutions. It offers Alocril and Elestat ophthalmic solutions for the treatment of itch associated with allergic conjunctivitis. The company’s neuromodulator product, Botox, is used therapeutically in the treatment of neuromuscular disorders. Allergan’s skin care products include: Tazorac gel used for the treatment of plaque psoriasis; Azelex cream used in the topical treatment of mild to moderate inflammatory acne; Avage, a tazarotene cream indicated for the treatment of facial fine wrinkling, mottled hypo and hyperpigmentation, and benign facial lentigines; Prevagetm, an antioxidant cream, that reduces the appearance of fine lines and wrinkles, as well as provides protection against sun damage, air pollution, and cigarette smoke; and glycolic acid-based products. Allegran, Inc. has a strategic research collaboration agreement with ExonHit Therapeutics to identify new molecular targets based on ExonHits’ gene profiling DATAS technology. Allegran was incorporated in 1948 and is headquartered in Irvine, California.

Latest Headlines

Final Glance: Medical Devices companies (AP)

ALLERGAN INC Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online)

Midday Glance: Medical Devices companies (AP)

Early Glance: Medical Devices companies (AP)

Cramer: J&J's Mentor Deal Makes Sense (TheStreet.com TV)

[$$] J&J to Acquire Breast-Implant Maker (at The Wall Street Journal Online)

QLT shares buck falling market on buyback (AP)

Final Glance: Medical Devices companies (AP)

J&J to buy breast implant maker Mentor for $1.07B (AP)

[$$] J&J to Buy Implant Maker Mentor for $1.07 Billion (at The Wall Street Journal Online)